SAN MARINO, Calif., June 15, 2011 /PRNewswire/ — Viral
Genetics, Inc., (Pinksheets: VRAL) is pleased to announce that
Boston-based Research 2.0 today released an 8-page report focused
on the Company’s majority-owned subsidiary, VG Energy, Inc. The
report is available on the company’s website at
www.viralgenetics.com/investors/research20_June2011.php and is
also distributed over the internet and through institutional
platforms including FactSet, CapitalIQ, and TheMarkets.com.
Research 2.0 is pioneering a new “open professional” model of
investment research which gives companies a direct path to quality
independent institutional research coverage via an annual retainer
and making that research broadly available to all potential
investors on the Internet and in open social and professional
“As with any coverage like this we will let the report and
analysts speak for themselves, but we are very pleased to see the
exciting new developments at VG Energy get professionally analyzed,
described and evaluated for all of our stakeholders,” said Viral
Genetics and VG Energy CEO, Haig Keledjian.
About Viral Genetics, Inc.
San Marino, California-based Viral Genetics discovers drug
therapies from two platform technologies based on over 60 patents:
Metabolic Disruption (MDT) and Targeted Peptides (TPT). Founded in
1994, the biotech company is researching treatments for HIV/AIDS,
Lyme Disease, Strep, Staph and drug resistant cancer. A
majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated
to exploring biofuel and agricultural applications for the MDT
platform. For more information, visit www.viralgenetics.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that
involve risks a